Skip to main content

Table 5 Late toxicities

From: A phase I dose-escalation trial of stereotactic body radiotherapy using 4 fractions for patients with localized prostate cancer

 

Level 1 (n = 9)

Level 2 (n = 9)

Level 3 (n = 9)

G1

G2

G1

G2

G1

G2

RTOG

 GU

3

(33.3%)

1

(11.1%)

4

(44.4%)

0

(0.0%)

4

(44.4%)

0

(0.0%)

 GI

2

(22.2%)

0

(0.0%)

0

(0.0%)

0

(0.0%)

2

(22.2%)

1

(11.1%)

Micturition pain

0

(0.0%)

0

(0.0%)

1

(11.1%)

0

(0.0%)

0

(0.0%)

0

(0.0%)

Frequency

4

(44.4%)

0

(0.0%)

4

(44.4%)

0

(0.0%)

4

(44.4%)

0

(0.0%)

Urinary incontinence

1

(11.1%)

0

(0.0%)

1

(11.1%)

0

(0.0%)

0

(0.0%)

0

(0.0%)

Retention

0

(0.0%)

1

(11.1%)

0

(0.0%)

0

(0.0%)

0

(0.0%)

0

(0.0%)

Hematuria

0

(0.0%)

0

(0.0%)

1

(11.1%)

0

(0.0%)

0

(0.0%)

0

(0.0%)

Stricture

0

(0.0%)

0

(0.0%)

0

(0.0%)

0

(0.0%)

0

(0.0%)

0

(0.0%)

Proctitis

0

(0.0%)

0

(0.0%)

0

(0.0%)

0

(0.0%)

1

(11.1%)

0

(0.0%)

Fecal incontinence

0

(0.0%)

0

(0.0%)

0

(0.0%)

0

(0.0%)

0

(0.0%)

0

(0.0%)

Diarrhea

0

(0.0%)

0

(0.0%)

0

(0.0%)

0

(0.0%)

0

(0.0%)

0

(0.0%)

Rectal hemorrhage

2

(22.2%)

0

(0.0%)

0

(0.0%)

0

(0.0%)

1

(11.1%)

1

(11.1%)

  1. GU Genitourinary toxicity, GI Gastrointestinal toxicity, RTOG Radiation therapy oncology group